Identification
NamePrasterone sulfate
Accession NumberDB05804
TypeSmall Molecule
GroupsInvestigational
Description

DHEA sulfate is the major steroid of the fetal adrenal. DHEA-S is the principal adrenal androgen and is secreted together with cortisol under the control of ACTH and prolactin. DHEA-S is elevated with hyperprolactinemia.

Structure
Thumb
Synonyms
(3-beta)-3-(Sulfooxy)androst-5-en-17-one
17-Ketoandrost-5-en-3beta-yl sulfate
17-oxoandrost-5-en-3β-yl hydrogen sulphate
3-O-Sulfodehydroepiandrosterone
3beta-Hydroxyandrost-5-en-17-one 3-sulfate
Androst-5-en-17-on-3beta-yl sulfuric acid
Dehydroepiandrosterone 3-sulfate
Dehydroepiandrosterone monosulfate
Dehydroepiandrosterone sulfate
Dehydroepiandrosterone sulphate
Dehydroisoandrosterone sulfate
Dehydroisoandrosterone-3-sulfate
DHEA sulfate
DHEA sulphate
DHEA-S
Prasterone sulphate
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
InflarestNot Available
Brand mixturesNot Available
Categories
UNII57B09Q7FJR
CAS number651-48-9
WeightAverage: 368.488
Monoisotopic: 368.165744696
Chemical FormulaC19H28O5S
InChI KeyCZWCKYRVOZZJNM-USOAJAOKSA-N
InChI
InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
IUPAC Name
[(1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-5-yl]oxidanesulfonic acid
SMILES
Pharmacology
Indication

Investigated for use/treatment in asthma and burns and burn infections.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

The low levels of dehydroepiandrosterone sulfate(DHEA-S)is associated with unfavorable levels of several strong cardiovascular disease risk factors, such as lipids and blood pleasure, which are components of the metabolic syndrome, and insulin levels. DHEA-S deficiency is risk factors of obesity and insulin resistance, but it is not clear, whether this possible influence is independent.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Aromatase deficiencyDiseaseSMP00565
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with dehydroepiandrosterone sulfate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with dehydroepiandrosterone sulfate.Approved
Aldesleukindehydroepiandrosterone sulfate may decrease the antineoplastic activities of Aldesleukin.Approved
Aluminum hydroxideThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with dehydroepiandrosterone sulfate.Approved
AmiodaroneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin Bdehydroepiandrosterone sulfate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with dehydroepiandrosterone sulfate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with dehydroepiandrosterone sulfate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with dehydroepiandrosterone sulfate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with dehydroepiandrosterone sulfate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with dehydroepiandrosterone sulfate.Approved, Investigational
AprepitantThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with dehydroepiandrosterone sulfate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with dehydroepiandrosterone sulfate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with dehydroepiandrosterone sulfate.Approved, Investigational
BazedoxifeneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Bazedoxifene.Approved, Investigational
Bendroflumethiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with dehydroepiandrosterone sulfate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with dehydroepiandrosterone sulfate.Investigational
Bismuth SubcitrateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with dehydroepiandrosterone sulfate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with dehydroepiandrosterone sulfate.Investigational
Bumetanidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with dehydroepiandrosterone sulfate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Ceritinibdehydroepiandrosterone sulfate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
Chlorothiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Chlorotrianisene.Withdrawn
Chlorthalidonedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of dehydroepiandrosterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with dehydroepiandrosterone sulfate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with dehydroepiandrosterone sulfate.Approved
CobicistatThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of dehydroepiandrosterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of dehydroepiandrosterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with dehydroepiandrosterone sulfate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with dehydroepiandrosterone sulfate.Investigational
DarunavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with dehydroepiandrosterone sulfate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
DienestrolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with dehydroepiandrosterone sulfate.Approved
Dihydrotestosteronedehydroepiandrosterone sulfate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with dehydroepiandrosterone sulfate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with dehydroepiandrosterone sulfate.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with dehydroepiandrosterone sulfate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with dehydroepiandrosterone sulfate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with dehydroepiandrosterone sulfate.Approved
EquolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with S Equol.Investigational
EstradiolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estrone.Approved
Etacrynic aciddehydroepiandrosterone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with dehydroepiandrosterone sulfate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with dehydroepiandrosterone sulfate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with dehydroepiandrosterone sulfate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with dehydroepiandrosterone sulfate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with dehydroepiandrosterone sulfate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with dehydroepiandrosterone sulfate.Approved
FenthionThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with dehydroepiandrosterone sulfate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with dehydroepiandrosterone sulfate.Vet Approved
Fluoxymesteronedehydroepiandrosterone sulfate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with dehydroepiandrosterone sulfate.Approved, Investigational
FosaprepitantThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Fosphenytoin.Approved
Furosemidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with dehydroepiandrosterone sulfate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved, Investigational
Hydrochlorothiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with dehydroepiandrosterone sulfate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with dehydroepiandrosterone sulfate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with dehydroepiandrosterone sulfate.Approved
IdelalisibThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of dehydroepiandrosterone sulfate.Approved
Indapamidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with dehydroepiandrosterone sulfate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with dehydroepiandrosterone sulfate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with dehydroepiandrosterone sulfate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with dehydroepiandrosterone sulfate.Withdrawn
ItraconazoleThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with dehydroepiandrosterone sulfate.Experimental
KetoconazoleThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with dehydroepiandrosterone sulfate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with dehydroepiandrosterone sulfate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with dehydroepiandrosterone sulfate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with dehydroepiandrosterone sulfate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with dehydroepiandrosterone sulfate.Approved
LumacaftorThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with dehydroepiandrosterone sulfate.Approved, Investigational
MagaldrateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with dehydroepiandrosterone sulfate.Approved
Magnesium TrisilicateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with dehydroepiandrosterone sulfate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with dehydroepiandrosterone sulfate.Approved
MefloquineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with dehydroepiandrosterone sulfate.Approved
MestranolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with dehydroepiandrosterone sulfate.Withdrawn
MethallenestrilThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Methanesulfonyl Fluoride.Investigational
Methyclothiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyltestosteronedehydroepiandrosterone sulfate may increase the fluid retaining activities of Methyltestosterone.Approved
Metolazonedehydroepiandrosterone sulfate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of dehydroepiandrosterone sulfate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Minaprine.Approved
MitotaneThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with dehydroepiandrosterone sulfate.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with dehydroepiandrosterone sulfate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with dehydroepiandrosterone sulfate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with dehydroepiandrosterone sulfate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with dehydroepiandrosterone sulfate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
NefazodoneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with dehydroepiandrosterone sulfate.Approved
NevirapineThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with dehydroepiandrosterone sulfate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with dehydroepiandrosterone sulfate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with dehydroepiandrosterone sulfate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with dehydroepiandrosterone sulfate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with dehydroepiandrosterone sulfate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with dehydroepiandrosterone sulfate.Vet Approved
Oxandrolonedehydroepiandrosterone sulfate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with dehydroepiandrosterone sulfate.Approved
Oxymetholonedehydroepiandrosterone sulfate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with dehydroepiandrosterone sulfate.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with dehydroepiandrosterone sulfate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with dehydroepiandrosterone sulfate.Approved, Investigational
PhenytoinThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Piretanidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with dehydroepiandrosterone sulfate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with dehydroepiandrosterone sulfate.Approved, Investigational
Polyestradiol phosphateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Polyestradiol phosphate.Approved
Polythiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with dehydroepiandrosterone sulfate.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with dehydroepiandrosterone sulfate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Quinestrol.Approved
Quinethazonedehydroepiandrosterone sulfate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with dehydroepiandrosterone sulfate.Experimental, Investigational
RifabutinThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with CDX-110.Investigational
RitonavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with dehydroepiandrosterone sulfate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with dehydroepiandrosterone sulfate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with dehydroepiandrosterone sulfate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with dehydroepiandrosterone sulfate.Approved
SaquinavirThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with dehydroepiandrosterone sulfate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with dehydroepiandrosterone sulfate.Investigational
St. John's WortThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with St. John's Wort.Nutraceutical
Stanozololdehydroepiandrosterone sulfate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with dehydroepiandrosterone sulfate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with dehydroepiandrosterone sulfate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with dehydroepiandrosterone sulfate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with dehydroepiandrosterone sulfate.Withdrawn
TelithromycinThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with dehydroepiandrosterone sulfate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with dehydroepiandrosterone sulfate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with dehydroepiandrosterone sulfate.Approved
Testosteronedehydroepiandrosterone sulfate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with dehydroepiandrosterone sulfate.Approved
TiboloneThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with dehydroepiandrosterone sulfate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with dehydroepiandrosterone sulfate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with dehydroepiandrosterone sulfate.Approved
Torasemidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with dehydroepiandrosterone sulfate.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Trichlorfon.Vet Approved
Trichlormethiazidedehydroepiandrosterone sulfate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with dehydroepiandrosterone sulfate.Investigational, Withdrawn
VoriconazoleThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarindehydroepiandrosterone sulfate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with dehydroepiandrosterone sulfate.Approved
ZeranolThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with dehydroepiandrosterone sulfate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with dehydroepiandrosterone sulfate.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Altman R, Motton DD, Kota RS, Rutledge JC: Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. 2008 Feb-Mar;48(2-3):76-84. doi: 10.1016/j.vph.2007.12.002. Epub 2007 Dec 15. [PubMed:18255343 ]
  2. Rabijewski M, Papierska L, Kozakowski J, Zgliczynski W: [The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men]. Endokrynol Pol. 2007 Nov-Dec;58(6):496-504. [PubMed:18205106 ]
  3. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentMinor burns1
3SuspendedTreatmentPlasmodium Infections1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00806 mg/mLALOGPS
logP0.49ALOGPS
logP3.42ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)-1.4ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.65 m3·mol-1ChemAxon
Polarizability39.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9388
Caco-2 permeable-0.6601
P-glycoprotein substrateNon-substrate0.507
P-glycoprotein inhibitor IInhibitor0.6926
P-glycoprotein inhibitor IINon-inhibitor0.9548
Renal organic cation transporterNon-inhibitor0.7909
CYP450 2C9 substrateNon-substrate0.8322
CYP450 2D6 substrateNon-substrate0.8338
CYP450 3A4 substrateSubstrate0.6799
CYP450 1A2 substrateNon-inhibitor0.8203
CYP450 2C9 inhibitorNon-inhibitor0.84
CYP450 2D6 inhibitorNon-inhibitor0.882
CYP450 2C19 inhibitorNon-inhibitor0.8117
CYP450 3A4 inhibitorNon-inhibitor0.9481
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7575
Ames testNon AMES toxic0.5802
CarcinogenicityNon-carcinogens0.586
BiodegradationNot ready biodegradable0.9519
Rat acute toxicity2.4168 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5859
hERG inhibition (predictor II)Inhibitor0.5409
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSulfated steroids
Direct ParentSulfated steroids
Alternative ParentsAndrostane steroids / 17-oxosteroids / Delta-5-steroids / Sulfuric acid monoesters / Alkyl sulfates / Ketones / Organic oxides / Hydrocarbon derivatives
SubstituentsSulfated steroid skeleton / Androstane-skeleton / 17-oxosteroid / Oxosteroid / Delta-5-steroid / Sulfuric acid ester / Alkyl sulfate / Sulfuric acid monoester / Sulfate-ester / Organic sulfuric acid or derivatives
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptorssteroid sulfate, 17-oxo steroid (CHEBI:16814 ) / sulfates, C19 steroids (androgens) and derivatives, Androgens (C04555 ) / Sulfates (LMST05020010 )

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Uniprot Name:
Aromatase
Molecular Weight:
57882.48 Da
References
  1. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER: Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab. 2007 May;3(5):414-21. [PubMed:17452968 ]
  2. ElBeltagy K, Honda K, Ozaki K, Misugi T, Tokuyama O, Kimura M, Kira Y, Ishiko O: In vitro effect of dehydroepiandrosterone sulfate on steroid receptors, aromatase, cyclooxygenase-2 expression, and steroid hormone production in preovulatory human granulosa cells. Fertil Steril. 2007 Oct;88(4 Suppl):1135-42. Epub 2007 Jun 4. [PubMed:17548088 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Uniprot Name:
Cytochrome P450 3A7
Molecular Weight:
57525.03 Da
References
  1. Bacsi K, Kosa JP, Borgulya G, Balla B, Lazary A, Nagy Z, Horvath C, Speer G, Lakatos P: CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int. 2007 Mar;80(3):154-9. Epub 2007 Mar 3. [PubMed:17334880 ]
  2. Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, Pols HA, Brinkmann AO, de Jong FH, Lamberts SW: A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab. 2005 Sep;90(9):5313-6. Epub 2005 Jun 28. [PubMed:15985487 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Uniprot Name:
Prostaglandin G/H synthase 2
Molecular Weight:
68995.625 Da
References
  1. ElBeltagy K, Honda K, Ozaki K, Misugi T, Tokuyama O, Kimura M, Kira Y, Ishiko O: In vitro effect of dehydroepiandrosterone sulfate on steroid receptors, aromatase, cyclooxygenase-2 expression, and steroid hormone production in preovulatory human granulosa cells. Fertil Steril. 2007 Oct;88(4 Suppl):1135-42. Epub 2007 Jun 4. [PubMed:17548088 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Uniprot Name:
Solute carrier family 22 member 8
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Uniprot Name:
Solute carrier organic anion transporter family member 1A2
Molecular Weight:
74144.105 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Uniprot Name:
Solute carrier organic anion transporter family member 1B1
Molecular Weight:
76447.99 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Uniprot Name:
Solute carrier organic anion transporter family member 1B3
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Uniprot Name:
Solute carrier organic anion transporter family member 2B1
Molecular Weight:
76709.98 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-dependent organic anion transmembrane transporter activity
Specific Function:
Transports sulfoconjugated steroid hormones, as well as taurolithocholic acid-3-sulfate and sulfoconjugated pyrenes in a sodium-dependent manner.
Gene Name:
SLC10A6
Uniprot ID:
Q3KNW5
Uniprot Name:
Solute carrier family 10 member 6
Molecular Weight:
41258.24 Da
References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011 ]
Drug created on November 18, 2007 11:27 / Updated on September 01, 2017 11:25